Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

26
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
26
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

22
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
22
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

21
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
21
Pericarditis IV: Nursing Management01:25

Pericarditis IV: Nursing Management

34
Pericarditis, an inflammation of the pericardium, necessitates diligent nursing management to ensure effective patient care and recovery. The initial step in managing pericarditis is a comprehensive patient medical assessment.The patient reports chest pain aggravated by breathing, coughing, and swallowing, which worsens when lying supine. The pain often improves when sitting up and leaning forward. Additional symptoms may include fever, malaise, and, in severe cases, signs of heart failure.
34
Pericarditis I: Introduction01:22

Pericarditis I: Introduction

18
Pericarditis is defined as the inflammation of the pericardium, the thin, sac-like membrane surrounding the heart. This condition can cause significant chest pain and other symptoms, often necessitating medical intervention. The pericardium has two layers: the inner visceral layer and the outer parietal layer, separated by a small amount of fluid that reduces friction during heartbeats.Types of PericarditisPericarditis can be classified into several types based on the duration and nature of the...
18
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

33
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
33

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Pharmaceutically Manufactured Cannabidiol in Recurrent Pericarditis: A Phase II Clinical Trial.

Journal of the American Heart Association·2026
Same author

CMR Detected Atrial Structural and Functional Remodeling in AF HFrEF: Ablation vs Medical Rate Control.

JACC. Clinical electrophysiology·2026
Same author

Left Ventricular Fibrosis in Atrial Fibrillation and Heart Failure with Reduced Ejection Fraction: A Comprehensive Review of Mechanisms, Clinical Implications, and Therapeutic Perspectives.

Heart rhythm·2026
Same author

Quantification of mitral regurgitation: from traditional methods to artificial intelligence.

Cardiovascular ultrasound·2026
Same author

Constrictive Pericarditis and Bilateral Pleural Effusions Unmasked in an HLA-B27 Positive Patient.

JACC. Case reports·2026
Same author

Yield and predictors of conversion on serial amyloid nuclear SPECT/CT in at-risk populations for transthyretin cardiac amyloidosis.

European heart journal. Imaging methods and practice·2026

Related Experiment Video

Updated: Aug 24, 2025

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.6K

The Role of Rilonacept in Recurrent Pericarditis.

Saberio Lo Presti1, Tarec K Elajami2, Reza Reyaldeen1

  • 1Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.

Heart International
|October 24, 2022
PubMed
Summary
This summary is machine-generated.

Rilonacept, an IL-1 inhibitor, effectively treats recurrent pericarditis by reducing symptoms and inflammation. This novel therapy shows promise for managing steroid-dependent or colchicine-refractory cases, improving patient quality of life.

Keywords:
Recurrent pericarditisinterleukin-1 inhibitorrilonacept

More Related Videos

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.3K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

Related Experiment Videos

Last Updated: Aug 24, 2025

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.6K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.3K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

Area of Science:

  • Cardiology
  • Immunology
  • Pharmacology

Background:

  • Recurrent pericarditis significantly impacts quality of life.
  • Autoinflammatory pathways, particularly IL-1α and IL-1β, are key in its pathophysiology.
  • The IL-1 pathway presents a promising therapeutic target.

Purpose of the Study:

  • To review the bio-action of rilonacept in treating recurrent pericarditis.
  • To highlight rilonacept's role as an IL-1 trap.
  • To discuss its efficacy in refractory and steroid-dependent cases.

Main Methods:

  • Review of the RHAPSODY phase III clinical trial.
  • Analysis of rilonacept's mechanism of action as an IL-1 inhibitor.
  • Assessment of clinical outcomes and safety profile.

Main Results:

  • Rilonacept significantly reduced symptoms, inflammatory markers, and recurrent episodes.
  • Successful steroid withdrawal was increased with rilonacept treatment.
  • The drug demonstrated a favorable safety profile, with injection site reactions being common.

Conclusions:

  • Rilonacept offers a new therapeutic option for recurrent pericarditis.
  • It effectively targets the IL-1 pathway, addressing underlying inflammation.
  • This drug may become a standard of care, potentially used as monotherapy.